A prospective quitting meta-analysis chooses studies before their results are known
Check the order of study selection and result availability before treating prospective, living and individual-data reviews as the same thing.
No Vape · Updated

Find what was prospective
A headline may use prospective for a cohort followed forward, an analysis plan written in advance, or a planned synthesis of separate trials. Locate the unit being planned. If the claim concerns a meta-analysis, ask when the contributing studies were selected relative to knowledge of their relevant results. A study planned before its own data collection answers a different timing question.
Cochrane’s Chapter 22 defines prospective meta-analysis through that pre-result study-selection sequence. We use its methodological distinction only. The source does not provide a quitting effect for this page or establish that a particular review met the definition. A registered review protocol alone does not tell you what results the team already knew when selecting studies.
Cochrane: Cochrane Handbook Chapter22 — Prospectively planned meta-analysis
Build a study-by-study chronology
Create a short reading table with study identity, acceptance into the synthesis, and relevant results becoming available. Use documented dates or explicit statements rather than dates guessed from journal publication. Publication can follow earlier knowledge of results. If a necessary stage is unreported, mark it unknown and retain the exact document that leaves the question open.
Imagine an invented collaboration agreeing to include two ongoing studies before either relevant result is known. Another study is considered only after its outcome has been announced. These records should not all acquire the same prospective label without explanation. The fictional example tests a chronology; it supplies no actual review, participant count, intervention benefit or allegation of selective conduct.
Keep related review features on separate lines
A living review concerns continuing updates. An individual-participant-data review concerns the information obtained for synthesis. Neither label alone establishes pre-result eligibility decisions. A project could have more than one of these features, but each needs its own description. Do not call an ordinary updated review prospective simply because the next update has not yet appeared.
Also locate whether the contributing trials retained different local protocols. A collaboration can coordinate selected definitions without becoming one multicenter trial under a single protocol. Questions about population, outcome timing, comparators and missing information remain relevant. Advance planning can address a particular selection concern while leaving other design and interpretation questions for the actual report.
State a bounded assembly claim
Your final note can say which studies were documented as eligible before relevant results were known, what subsequent additions occurred, and how the report handled them. If only the label is visible, say that the timing remains unverified. You do not need access to private interim data or correspondence to avoid overstating the public account.
For a consequential health decision, ask an appropriate professional to interpret the complete evidence. This guide does not conduct a formal review appraisal or recommend a quitting treatment. Its useful output is an auditable order of events: selection, result knowledge and synthesis. That prevents a promising planning feature from silently becoming proof that an intervention works for you.
Sources and scope
Sources inform the guidance. The worksheets and examples are No Vape editorial suggestions, not tested treatments.
Written with AI assistance and checked against the cited sources. No clinical review is claimed. This guide covers practical planning, not individual medical treatment. How we research and write